ACADIA Pharmaceuticals Inc. (ACAD) Balance Sheet

The move from a deficit-driven position toward a larger equity base suggests the commercial ramp of Nuplazid and Daybue is finally flowing into the balance sheet. Liabilities have remained relatively flat despite rising revenue, which may imply disciplined working capital management, though the reduction in accumulated deficit from roughly $2.4B to $1.7B still leaves a large historical loss base that warrants monitoring.

A current ratio consistently above 2 suggests short-term obligations are well covered by liquid assets and receivables. However, the sizeable quarter-to-quarter swings in cash balances suggest that working capital timing, rather than steady accumulation, drives the reported liquidity position. Investors should monitor whether the buffer holds if commercial launch spending or pipeline costs rise.

Debt-to-equity has trended down from 0.11 in 2024Q2, which suggests equity growth has outpaced borrowing rather than debt being retired aggressively. The low leverage reduces refinancing risk and interest rate sensitivity, though the debt balance itself is small enough that its composition and maturity profile may be less consequential than the company's cash generation capacity.

Rising goodwill alongside stable PP&E is consistent with an asset-light commercial model that has grown through acquisition, as opposed to internal capacity investment. This may indicate impairment exposure if commercial performance of acquired products falls short of expectations, and investors should watch for any changes in goodwill valuation assumptions.